Tap a claim on the ring to put it at the centre.
← The patent system rewards novel chemical matter and not novel biology,…
17 connected korrents · 17 moments on record from 8 Mar 2012 to 14 Aug 2026.
Everything filed under design
design
Everything filed under Psychotherapy
Psychotherapy
Everything filed under benchmarks
benchmarks
Everything filed under simplicity
simplicity Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Same subject Read this korrent: The patent system rewards novel chemical matter and not novel biology, so nobody is paid for validating a new drug target. The patent system rewards novel chemical matter and not novel biology, so nobody is paid for validating a new drug target. Last stated 2 months ago
21 Jul 2026
RT
Ruxandra Teslo — holds since 2026-07-21 — tap for who they are
Same subject: The hard part of drug discovery is knowing what to make - which target is worth drugging - not designing the molecule. — tap to centre the map on it The hard part of drug discovery is knowing what to make - which target is worth drugging - not designing the molecule. Last stated 2 months ago
21 Jul 2026
AT
Alex Telford — holds since 2023-12-23 — tap for who they are
RT
Ruxandra Teslo — holds since 2026-07-21 — tap for who they are
Same subject: Drug companies pile onto the same few already-validated targets, so far less of biology gets explored than could be. — tap to centre the map on it Drug companies pile onto the same few already-validated targets, so far less of biology gets explored than could be. Last stated 2 months ago
21 Jul 2026
RT
Ruxandra Teslo — holds since 2026-07-21 — tap for who they are
Same subject: Every new drug has to beat the cheap generics that came before it, and that competition with our own back catalogue is why drug discovery gets harder over time. — tap to centre the map on it Every new drug has to beat the cheap generics that came before it, and that competition with our own back catalogue is why drug discovery gets harder over time. Last stated 15 years ago
8 Mar 2012
DL
Derek Lowe — holds since 2012-03-08 — tap for who they are
Same subject: How long a trial takes decides which diseases get drugs at all, because capital flows to the indications whose endpoints can be measured quickly. — tap to centre the map on it How long a trial takes decides which diseases get drugs at all, because capital flows to the indications whose endpoints can be measured quickly. Last stated 6 months ago
28 Feb 2026
AT
Alex Telford — holds since 2023-12-23 — tap for who they are
RT
Ruxandra Teslo — holds since 2026-02-28 — tap for who they are
Same subject: There is no factory you can pay to produce biological data; each new dataset requires inventing a new scientific method first. — tap to centre the map on it There is no factory you can pay to produce biological data; each new dataset requires inventing a new scientific method first. Last stated 3 months ago
10 Jun 2026
MZ
Mark Zuckerberg — holds since 2026-06-10 — tap for who they are
Same subject: A compound's AI origin story is not by itself a reason to expect it to do better in the clinic. — tap to centre the map on it A compound's AI origin story is not by itself a reason to expect it to do better in the clinic. Last stated 2 years ago
13 May 2024
DL
Derek Lowe — holds since 2024-05-13 — tap for who they are
Same subject: Companies do not have sufficient incentives to mitigate the major risks of AI, and competition between them is driving corner-cutting. — tap to centre the map on it Companies do not have sufficient incentives to mitigate the major risks of AI, and competition between them is driving corner-cutting. Last stated 2 years ago
15 Feb 2025
MB
Miles Brundage — holds since 2025-02-15 — tap for who they are
Same subject: Industry benchmarks are a dangerous target because every company defines the underlying metric differently. — tap to centre the map on it Industry benchmarks are a dangerous target because every company defines the underlying metric differently. Last stated 2 years ago
19 Jan 2025
EV
Elena Verna — holds since 2025-01-19 — tap for who they are
Same subject: A blank chat box is lazy: it violates the first rule of a good user experience, that it is obvious what you can do. — tap to centre the map on it A blank chat box is lazy: it violates the first rule of a good user experience, that it is obvious what you can do. Last stated a year ago
12 May 2025
JZ
Julie Zhuo — holds since 2025-05-12 — tap for who they are
Same subject: A company deserves everyone in it, the chief executive included, to spend as much time as possible in their zone of genius — which is an org design problem. — tap to centre the map on it A company deserves everyone in it, the chief executive included, to spend as much time as possible in their zone of genius — which is an org design problem. Last stated a year ago
23 Mar 2025
RV
Rahul Vohra — holds since 2025-03-23 — tap for who they are
Same subject: A computer meant for anyone has to be understandable without a manual, and it has to be friendly. — tap to centre the map on it A computer meant for anyone has to be understandable without a manual, and it has to be friendly. Last stated 4 weeks ago
14 Aug 2026
SK
Susan Kare — holds since 2026-08-14 — tap for who they are
Same subject: "Evidence-based therapy" is a branding term rather than a scientific one, and in practice it is a code word for "not psychodynamic". — tap to centre the map on it "Evidence-based therapy" is a branding term rather than a scientific one, and in practice it is a code word for "not psychodynamic". Last stated 13 years ago
2 Oct 2013
JS
Jonathan Shedler — holds since 2013-10-02 — tap for who they are
Same subject: A prescriber cannot outsource containment to the therapy hour: the emotional and relational dynamics are part of prescribing, not an intrusion on it. — tap to centre the map on it A prescriber cannot outsource containment to the therapy hour: the emotional and relational dynamics are part of prescribing, not an intrusion on it. Last stated 2 months ago
5 Jul 2026
AA
Awais Aftab — holds since 2026-07-05 — tap for who they are
Same subject: A therapy is only shown to be more effective if it is compared against another treatment intended to help, not against a control nobody expected to work. — tap to centre the map on it A therapy is only shown to be more effective if it is compared against another treatment intended to help, not against a control nobody expected to work. Last stated 2 years ago
11 Sept 2024
SM
Scott D. Miller — holds since 2024-09-11 — tap for who they are
Same subject: After a decade of Swiss minimalism, design is about to swing back to something far more expressive. — tap to centre the map on it After a decade of Swiss minimalism, design is about to swing back to something far more expressive. Last stated 11 months ago
16 Oct 2025
DF
Dylan Field — holds since 2025-10-16 — tap for who they are
Same subject: AI acceleration threatens 'less software': without the constraint of scarce hours, even 37signals will likely build too much. — tap to centre the map on it AI acceleration threatens 'less software': without the constraint of scarce hours, even 37signals will likely build too much. Last stated a month ago
26 Jul 2026
DH
David Heinemeier Hansson — holds since 2026-07-26 — tap for who they are
Same subject: Better design does not mean more design: the most obvious designs are often invisible. — tap to centre the map on it Better design does not mean more design: the most obvious designs are often invisible. Last stated 3 years ago
16 Nov 2023
JZ
Julie Zhuo — holds since 2023-11-16 — tap for who they are
At the centre
The patent system rewards novel chemical matter and not novel biology, so nobody is paid for validating a new drug target.
Holds RT Ruxandra TesloRead this korrent →
The hard part of drug discovery is knowing what to make - which target is worth drugging - not designing the molecule.
Holds AT Alex TelfordRT Ruxandra Teslo
Drug companies pile onto the same few already-validated targets, so far less of biology gets explored than could be.
Holds RT Ruxandra Teslo
Every new drug has to beat the cheap generics that came before it, and that competition with our own back catalogue is why drug discovery gets harder over time.
Holds DL Derek Lowe
How long a trial takes decides which diseases get drugs at all, because capital flows to the indications whose endpoints can be measured quickly.
Holds AT Alex TelfordRT Ruxandra Teslo
There is no factory you can pay to produce biological data; each new dataset requires inventing a new scientific method first.
Holds MZ Mark Zuckerberg
A compound's AI origin story is not by itself a reason to expect it to do better in the clinic.
Holds DL Derek Lowe
Companies do not have sufficient incentives to mitigate the major risks of AI, and competition between them is driving corner-cutting.
Holds MB Miles Brundage
Industry benchmarks are a dangerous target because every company defines the underlying metric differently.
Holds EV Elena Verna
A blank chat box is lazy: it violates the first rule of a good user experience, that it is obvious what you can do.
Holds JZ Julie Zhuo
A company deserves everyone in it, the chief executive included, to spend as much time as possible in their zone of genius — which is an org design problem.
Holds RV Rahul Vohra
A computer meant for anyone has to be understandable without a manual, and it has to be friendly.
Holds SK Susan Kare
"Evidence-based therapy" is a branding term rather than a scientific one, and in practice it is a code word for "not psychodynamic".
Holds JS Jonathan Shedler
A prescriber cannot outsource containment to the therapy hour: the emotional and relational dynamics are part of prescribing, not an intrusion on it.
Holds AA Awais Aftab
A therapy is only shown to be more effective if it is compared against another treatment intended to help, not against a control nobody expected to work.
Holds SM Scott D. Miller
After a decade of Swiss minimalism, design is about to swing back to something far more expressive.
Holds DF Dylan Field
AI acceleration threatens 'less software': without the constraint of scarce hours, even 37signals will likely build too much.
Holds
Better design does not mean more design: the most obvious designs are often invisible.
Holds JZ Julie Zhuo